Skip to main content

Endometriosis is a painful and debilitating condition that affects one in every ten women. Despite being a common health issue, there are currently limited treatment options available beyond pain management and surgery.

However, there is hope on the horizon with Swiss biotech company FimmCyte. FimmCyte has a clear vision to develop the first disease-modifying treatment for endometriosis. Their innovative approach is based on a non-hormonal, antibody-based therapy developed by co-founders Valentina Vongrad and Mohaned Shilaih in the lab of Professor Brigitte Leeners at the University Hospital Zurich.

Their therapy has shown exceptional promise in pre-clinical studies, demonstrating effectiveness in both in-vivo and ex-vivo models. This is particularly significant as there is currently no immune-based therapy for endometriosis available.

FimmCyte’s commitment to bringing a much-needed solution to women with endometriosis has been strengthened by the appointment of Maureen Cronin as their Chief Medical Officer. With her wealth of experience in the biotech industry, Cronin will undoubtedly play a vital role in bringing the therapy to market.

FimmCyte’s progress has been made possible through a combination of dilutive and non-dilutive funding from prestigious institutions such as the Bio Innovation Institute, VentureKick, USZ, Gebert Rüf Stiftung, and Innosuisse. This financial support has enabled the company to advance their research and development, bringing them one step closer to their goal of providing a disease-modifying treatment for endometriosis.

BaseLaunch is excited to welcome FimmCyte as our newest portfolio company!

Share this article

View all news

Sign up to receive our newsletter in your inbox.